LOGIN  |  REGISTER
Amneal Pharmaceuticals

Poseida Therapeutics (NASDAQ: PSTX) Stock Quote

Last Trade: US$3.19 0.11 3.57
Volume: 689,878
5-Day Change: 7.41%
YTD Change: -5.06%
Market Cap: US$307.800M

Latest News From Poseida Therapeutics

SAN DIEGO , March 25, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Syed Rizvi , M.D., as Chief Medical Officer effective April 1, 2024 . Dr. Rizvi is a seasoned executive with over 20 years of experience across all stages of drug development,... Read More
SAN DIEGO , March 19, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company's President and Chief Executive Officer, Kristin Yarema , Ph.D., will participate in a virtual fireside chat at the H.C. Wainwright 2 nd Annual Cell Therapy Virtual Conference on... Read More
Data Describing Activity of P-BCMA-ALLO1 in BCMA-Experienced Patients to be Presented at Upcoming AACR Meeting SAN DIEGO , March 13, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the... Read More
Lead asset P-BCMA-ALLO1 Phase 1 clinical trial data presented at ASH 2023 demonstrated 82% ORR and favorable emerging safety and reliability profile Initiated clinical trial of Phase 1 P-CD19CD20-ALLO1, the Company's first allogeneic dual CAR-T program Allogeneic CAR-T data to be presented at AACR in April 2024 describing activity of P-BCMA-ALLO1 in BCMA-experienced patients and comparison of lymphodepletion needs in heme... Read More
SAN DIEGO , March 4, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Compensation Committee of its Board of Directors granted an inducement award to an employee. This grant is made pursuant to the Company's 2022 Inducement Plan as an inducement material to a... Read More
Reported positive early clinical data for allogeneic myeloma cell therapy P-BCMA-ALLO1 at ASH 2023 supporting potential of T SCM -rich allogeneic CAR-T to offer a differentiated and compelling efficacy, safety, and reliability profile that could compete with autologous CAR-T Plan to report clinical data updates for P-BCMA-ALLO1and P-MUC1C-ALLO1 allogeneic CAR-T programs at scientific meetings in 2024 Expect to dose first... Read More
82% ORR and deep clinical responses from off-the-shelf, allogeneic BCMA-targeted CAR-T in heavily pretreated patients receiving adequate lymphodepletion 100% ORR in these patients who were not previously treated with a BCMA-targeted bispecific T cell-engaging antibody Favorable emerging safety and reliability profile, with all (100%) intent-to-treat (ITT) patients receiving therapy, no GvHD or dose-limiting toxicities and... Read More
Based upon progress in its allogeneic programs, the Company is announcing today acceleration and increased certainty of achieving upcoming milestones and payments related to the Roche Collaboration Closed strategic investment by Astellas Pharma in August 2023 , bringing additional funding of $50 million Acceptance of three poster presentations at the 65 th American Society of Hematology (ASH) Annual Meeting and Exposition in... Read More
SAN DIEGO , Nov. 7, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company will participate in the following upcoming investor conferences in November: Stifel 2023 Healthcare Conference Date: Tuesday, November 14, 2023 Time: 8:00am ET Piper Sandler 35 th... Read More
SAN DIEGO , Nov. 2, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the acceptance of three poster presentations at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held at the San Diego Convention Center in San Diego and virtually on... Read More
Mark Gergen to assume role of Executive Chairman of the Board of Directors of Poseida; Kristin Yarema , Ph.D., currently President, Cell Therapy, to be appointed President and CEO SAN DIEGO , Oct. 9, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of... Read More
SAN DIEGO , Sept. 5, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company will participate in the following upcoming investor conferences in September: H.C. Wainwright 25 th Annual Global Investment Conference Date: Tuesday, September 12, 2023 Time: 2:30pm... Read More
SAN DIEGO , Aug. 8, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced financial results for the second quarter ended June 30 , 2023. "In the second quarter, we continued to make strong progress while sharpening our focus on our clinical pipeline and research efforts,"... Read More
Poseida is a clinical-stage biotechnology company dedicated to advancing a new class of cancer cell therapy and gene therapy products using genetic engineering technologies Astellas to invest a total of $50 million to acquire approximately 8.8% of Poseida and to receive a right of exclusive negotiation and first refusal for any potential partnering of P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy product candidate for... Read More
$50 million strategic investment validates Poseida's proprietary technology and cell therapy approach and supports strategic and operational plans Implementing enhancements to ongoing allogeneic programs based upon significant learnings; adjusting guidance on clinical data updates Extending cash runway guidance SAN DIEGO , Aug. 7, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene... Read More
Believed to be the first FDA IND clearance of an allogeneic dual CAR-T therapy targeting CD19 and CD20 SAN DIEGO , July 5, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND)... Read More
SAN DIEGO , June 26, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced it is set to join both the broad-market Russell 3000 ® and small-cap Russell 2000 ® Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens... Read More
SAN DIEGO , June 1, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that its virtual Annual Meeting of Stockholders (the "Annual Meeting") will be held on Thursday, June 15, 2023 at 1:00 p.m. PT . The Annual Meeting will be held through a live webcast. Stockholders of... Read More
SAN DIEGO , May 23, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company's President of Gene Therapy, Brent Warner , will participate in a virtual fireside chat at the Stifel 2023 Tailoring Genes: Genetic Medicines Day on Tuesday, May 30, 2023 at 12:00pm PT... Read More
SAN DIEGO , May 22, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that two abstracts have been accepted for presentation at the 31 st Congress of the International Society on Thrombosis and Haemostasis (ISTH), being held in Montreal, Canada and virtually on June... Read More
Six presentations highlight significant advancements across the Company's Gene Therapy platform Preclinical data supports potential of P-OTC-101 to correct severe Ornithine Transcarbamylase Deficiency (OTCD) following a single dose Data presented establishes proof-of-concept for site-specific knock-in of a transgene using Cas-CLOVER™, Poseida's high-precision gene editing technology SAN DIEGO , May 18, 2023 /PRNewswire/ --... Read More
Highlighted significant research, preclinical advances and platform technology progress at third annual R&D Day Appointed Kristin Yarema , Ph.D., as President, Cell Therapy, adding extensive oncology and allogeneic T cell immunotherapy experience to the Company's leadership team SAN DIEGO , May 9, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new... Read More
SAN DIEGO , May 2, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that six data presentations, including two oral presentations, highlighting the Company's preclinical gene therapy programs and platforms will be presented at the American Society of Gene and Cell... Read More
SAN DIEGO , May 1, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that it will participate in the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023 at 3:15pm PT | 6:15pm ET in Las Vegas . A live webcast of the presentation will be available on the... Read More
SAN DIEGO , April 13, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Rafael G. Amado , M.D., to its Board of Directors, effective today. "I am thrilled to welcome Rafael to the Board of Directors of Poseida. His deep expertise and experience in... Read More
SAN DIEGO , April 11, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Compensation Committee of its Board of Directors granted an inducement award to Kristin Yarema , the Company's new President, Cell Therapy. This grant is made pursuant to the Company's 2022... Read More
SAN DIEGO , April 11, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that Kristin Yarema , Ph.D., has joined the Company as President, Cell Therapy effective today. "Kristin brings extensive biopharmaceutical experience in oncology and allogeneic T cell immunotherapy... Read More
Presented early data from Phase 1 trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 allogeneic CAR-T cell therapy programs at the European Society for Medical Oncology Immuno-Oncology 2022 Annual Congress (ESMO I-O) Highlighted preclinical data from P-FVIII-101 gene therapy program at the 64 th American Society of Hematology Annual Meeting & Exposition (ASH) SAN DIEGO , March 9, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc.... Read More
SAN DIEGO , March 1, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of five new members to its Gene Therapy Scientific Advisory Board (SAB). These world-class researchers will join George M. Church , Ph.D., Chair of Poseida's recently formed Gene... Read More
Virtual R&D Day featuring key opinion leaders and Poseida's leadership and scientific team members to be held today at 10:00am ET / 7:00am PT SAN DIEGO , Feb. 22, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company plans to highlight its clinical and... Read More
SAN DIEGO , Feb. 14, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company's Chief Executive Officer, Mark Gergen , will participate in a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023 , at 11:00 AM ET . A webcast... Read More
SAN DIEGO , Feb. 8, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company will host a virtual R&D Day at 10:00 am - 1:30 pm ET / 7:00 - 10:30 am PT on Wednesday , February 22, 2023. Poseida's third-annual R&D Day will feature its executive leadership and... Read More
Eric Ostertag , M.D., Ph.D., Founder and current Executive Chairman, to retire from the Board of Directors and remain a consultant to the Company SAN DIEGO , Jan. 31, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that Eric Ostertag , M.D., Ph.D., has resigned as... Read More
Data demonstrate that a non-viral, liver-directed gene therapy utilizing Super piggyBac ® (SPB) DNA Modification System achieved and maintained normalized human FVIII (hFVIII) activity following a single dose Data establishes preclinical proof of principle for treatment of Hemophilia A across all ages, which could potentially lead to a functional cure SAN DIEGO , Dec. 11, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc.... Read More
P-MUC1C-ALLO1 and P-BCMA-ALLO1 were well tolerated, with no dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), graft vs host disease (GVHD) or immune effector cell-associated neurotoxicity syndrome (ICANS) P-MUC1C-ALLO1 demonstrated encouraging clinical activity including an objective partial response in a breast cancer patient at the lowest dose P-BCMA-ALLO1 demonstrated responses in heavily pre-treated... Read More

COPYRIGHT ©2023 HEALTH STOCKS HUB